We study the responses to the platinum-based chemotherapeutic agents in clinical use, namely cisplatin, carboplatin and oxaliplatin, using three different prostate cancer cells lines representing different biological types of advanced prostate cancer (AR positive, AR negative, and expressing AR transcript variant). Here, AR is linked to prostate carcinoma.